CorMedix agreed to acquire Heron’s portfolio in a transaction featuring $145 million upfront consideration, signaling continued consolidation in niche specialty therapeutics. The deal, as reported in the market coverage, also coincided with Heron’s equity volatility, reflecting investor recalibration around remaining assets and future development priorities. For CorMedix, portfolio aggregation can accelerate scale and broaden pipeline coverage, while for Heron it functions as a de-risking move to monetize platform or product holdings amid ongoing capital needs in specialty biotech.